Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Published Study in the British Journal of Cancer Shows High Sensitivity and Specificity of Tethis’ Liquid Biopsy Platform in Early Stage Breast Cancer and The Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic Patients

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Published Study in the British Journal of Cancer

Tethis S.p.A announced the publication of a pilot study in early breast cancer showing the analytical performance of the novel SBS® liquid biopsy platform for the accurate identification of localized breast cancer patients and, for the first time, the identification and characterization of CTC clusters in non-metastatic patients.

The study, conducted in collaboration with the University Hospital Basel and led by Prof. Nicola Aceto, was performed using Tethis’ automated instrument for sample preparation in conjunction with Tethis’ proprietary SBS® slides and has been published in the peer-reviewed journal British Journal of Cancer, part of the Nature Portfolio journals. The full paper can be accessed here.

SBS®  liquid biopsy is a novel method that, thanks to the immediate and automated sample preparation, provides a specimen with an intact repertoire of clinically informative cells from fresh blood, allowing to achieve the highest sensitivity even in early cancer settings; this study has been conducted in blind analyzing 58 cases (30 healthy donors and 28 patients with localized breast cancer) and showed an overall sensitivity of 75%, with a 97% specificity in discriminating breast cancer patients from healthy individuals; the sensitivity was 81% on the 21 luminal-like patients, a relevant subgroup given that only ER and Her2 markers were used as a criteria for positivity. Moreover, for the first time, it was possible to identify CTC clusters in 5 out of 28 patients with early breast cancer, so far only described in metastatic settings.

“My team and I have been working on CTC clusters and their role in the metastatic process for years,” said Prof. Nicola Aceto, Ph.D., Professor of Molecular Oncology and Group Leader at the Swiss Federal Institute of Technology (ETH) Zurich. “To find them in a significant proportion of patients with localized cancer is groundbreaking, and although the study is small, it paves the way for larger trials to assess their clinical significance and evaluate the efficacy of anti CTC-clusters therapeutics currently in development.”

“We are thrilled about the results of this study,” said Roberta Carbone, Ph.D., Chief Scientific Officer at Tethis “which strongly suggests the feasibility of a non-invasive test for early breast cancer detection based on our proprietary liquid biopsy platform. We strongly believe that immediate, standardized and gentle blood sample preparation are the key drivers for success in a difficult setting such as early cancer detection, and that our platform properly addresses these needs.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine